1921
Volume 83, Issue 2
  • ISSN: 0002-9637
  • E-ISSN: 1476-1645

Abstract

Abstract.

We evaluated, through the prospective monitoring of 251 patients at Sadar Hospital in Bihar, India, the effectiveness and safety of 20 mg/kg body weight of liposomal amphotericin B for the treatment of visceral leishmaniasis. The treatment success rates for the intention-to-treat, per protocol, and intention-to-treat worse-case scenario analyses were 98.8%, 99.6%, and 81.3%, respectively. Nearly one-half of patients experienced mild adverse events, but only 1% developed serious but non–life-threatening lips swelling. The lost to follow-up rate was 17.5%. Our findings indicate that the 20 mg/kg body weight treatment dosage is effective and safe under routine program conditions. Given that the exorbitant cost of liposomal amphotericin B is a barrier to its widespread use, we recommend further study to monitor and evaluate a lowered dosage and a shorter treatment course.

Loading

Article metrics loading...

/content/journals/10.4269/ajtmh.2010.10-0156
2010-08-05
2017-07-23
Loading full text...

Full text loading...

/deliver/fulltext/14761645/83/2/357.html?itemId=/content/journals/10.4269/ajtmh.2010.10-0156&mimeType=html&fmt=ahah

References

  1. WHO, 2009. Communicable Diseases, Kala-Azar status in SEA Region. Available at: http://www.searo.who.int/en/section10/section2163_11668.htm. Accessed December 16, 2009.
  2. Desjeux P, , 2004. Leishmaniasis: current situation and new perspectives. Comp Immunol Microbiol Infect Dis 27: 305318.[Crossref]
  3. Olliaro PL, Guerin PJ, Gerstl S, Haaskjold AA, Rottingen JA, Sundar S, , 2005. Treatment options for visceral leishmaniasis: a systematic review of clinical studies done in India, 1980–2004. Lancet Infect Dis 5: 763774.[Crossref]
  4. Sundar S, More DK, Singh MK, Singh VP, Sharma S, Makharia A, Kumar PC, Murray HW, , 2000. Failure of pentavalent antimony in visceral leishmaniasis in India: report from the center of the Indian epidemic. Clin Infect Dis 31: 11041107.[Crossref]
  5. Lira R, Sundar S, Makharia A, Kenney R, Gam A, Saraiva E, Sacks D, , 1999. Evidence that the high incidence of treatment failures in Indian kala-azar is due to the emergence of antimony-resistant strains of Leishmania donovani . J Infect Dis 180: 564567.[Crossref]
  6. Sundar S, Singh VP, Sharma S, Makharia MK, Murry HW, , 1997. Response to interferon-gamma plus pentavalent antimony in Indian visceral leishmaniasis. J Infect Dis 176: 11171119.[Crossref]
  7. Thakur CP, Narayan S, Ranjan A, , 2004. Epidemiological, clinical and pharmacological study of antimony-resistant visceral leishmaniasis in Bihar, India. Indian J Med Res 120: 166172.
  8. Das VN, Ranjan A, Bimal S, Siddique NA, Pandey K, Kumar N, Verma N, Singh VP, Sinha PK, Bhattacharya SK, , 2005. Magnitude of unresponsiveness to sodium stibogluconate in the treatment of visceral leishmaniasis in Bihar. Natl Med J India 18: 131133.
  9. Thakur CP, Sinha GP, Pandey AK, Kumar N, Kumar P, Hassan SM, Narain S, Roy RK, , 1998. Do the diminishing efficacy and increasing toxicity of sodium stibogluconate in the treatment of visceral leishmaniasis in Bihar, India justify its continued use as a first-line drug? An observational study of 80 cases. Ann Trop Med Parasitol 92: 561569.[Crossref]
  10. Ahasan HA, Chowdhury MA, Azhar MA, Rafiqueuddin AK, Azad KA, , 1996. Deaths in visceral leishmaniasis (kala-azar) during treatment. Med J Malaysia 51: 2932.
  11. Sindermann H, Engel J, , 2006. Development of miltefosine as an oral treatment for leishmaniasis. Trans R Soc Trop Med Hyg 100 (Suppl 1): S17S20.[Crossref]
  12. Sundar S, Jha TK, Thakur CP, Engel J, Sindermann H, Fischer C, Junge K, Bryceson A, Berman J, , 2002. Oral miltefosine for Indian visceral leishmaniasis. N Engl J Med 347: 17391746.[Crossref]
  13. Sundar S, Murray HW, , 2005. Availability of miltefosine for the treatment of kala-azar in India. Bull World Health Organ 83: 394395.
  14. Sundar S, Jha TK, Thakur CP, Sinha PK, Bhattacharya SK, , 2007. Injectable paromomycin for visceral leishmaniasis in India. N Engl J Med 356: 25712581.[Crossref]
  15. Sundar S, Mehta H, Suresh AV, Singh SP, Rai M, Murray HW, , 2004. Amphotericin B treatment for Indian visceral leishmaniasis: conventional versus lipid formulations. Clin Infect Dis 38: 377383.[Crossref]
  16. WHO, 2005. Report of a WHO Informal Consultation on Liposomal Amphotericin B in the Treatment of Visceral Leishmaniasis. Available at: http://www.who.int/neglected_diseases/resources/AmBisomeReport.pdf. Accessed December 17, 2009.
  17. Sundar S, Rai M, , 2002. Advances in the treatment of leishmaniasis. Curr Opin Infect Dis 15: 593598.[Crossref]
  18. Rosenthal E, Marty P, , 2003. Recent understanding in the treatment of visceral leishmaniasis. J Postgrad Med 49: 6168.[Crossref]
  19. Sundar S, Agrawal G, Rai M, Makharia MK, Murray HW, , 2001. Treatment of Indian visceral leishmaniasis with single or daily infusions of low dose liposomal amphotericin B: randomised trial. BMJ 323: 419422.[Crossref]
  20. Sundar S, Jha TK, Thakur CP, Mishra M, Singh VP, Buffels R, , 2003. Single-dose liposomal amphotericin B in the treatment of visceral leishmaniasis in India: a multicenter study. Clin Infect Dis 37: 800804.[Crossref]
  21. Thakur CP, Pandey AK, Sinha GP, Roy S, Behbehani K, Olliaro P, , 1996. Comparison of three treatment regimens with liposomal amphotericin B (AmBisome) for visceral leishmaniasis in India: a randomised dose finding study. Trans R Soc Trop Med Hyg 90: 319322.[Crossref]
  22. Thakur CP, , 2001. A single dose treatment of kala-azar with AmBisome (amphotericin B lipid complex): a pilot study. Int J Antimicrob Agents 17: 6770.[Crossref]
  23. Sundar S, Jha TK, Thakur CP, Mishra M, Singh VR, Buffels R, , 2002. Low dose liposomal amphotericin B in refractory Indian visceral leishmaniasis: a multicenter study. Am J Trop Med Hyg 66: 143146.
  24. Sundar S, Chakravarty J, Agarwal D, Rai M, Murray HW, , 2010. Single-dose liposomal amphotericin B for visceral leishmaniasis in India. N Engl J Med 362: 504512.[Crossref]
  25. Bern C, Adler-Moore J, Berenguer J, Boelaert M, den Boer M, Davidson RN, Figueras C, Gradoni L, Kafetzis DA, Ritmeijer K, Rosenthal E, Royce C, Russo R, Sundar S, Alvar J, , 2006. Liposomal amphotericin B for the treatment visceral leishmaniasis. Clin Infect Dis 43: 917924.[Crossref]
  26. Collin S, Davidson R, Ritmeijer K, Keus K, Melaku Y, Kipngetich S, Davies C, , 2004. Conflict and kala-azar: determinants of adverse outcomes of kala-azar among patients in southern Sudan. Clin Infect Dis 38: 612619.[Crossref]
  27. Centres for Disease Control and Prevention, 2009. The SAS Program for the CDC Growth Charts. Available at: http://www.cdc.gov/nccdphp/dnpa/growthcharts/resources/sas.htm. Accessed April 14, 2009.
  28. National Cancer Institute Cancer Therapy Evaluation Program, 2003. Common Terminology Criteria for Adverse Events Version 3.0 (CTCAE) DCTD, NCI, NIH, DHHS. Available at: http://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/ctcaev3.pdf. Accessed December 21, 2009.
  29. Astellas Pharma US, Inc., 2007. AmBisome (Amphotericin B) Liposome for Injection. Available at: http://www.ambisome.com/index2.php?section=about&page=trials. Accessed March 19, 2009.
  30. Schmid C, Nkunku S, Merolle A, Vounatsou P, Burri C, , 2004. Efficacy of 10-day melarsoprol schedule 2 years after treatment for late-stage gambiense sleeping sickness. Lancet 364: 789790.[Crossref]
  31. Schmid C, Richer M, Bilenge CM, Josenando T, Chappuis F, Manthelot CR, Nangouma A, Doua F, Asumu PN, Simarro PP, Burri C, , 2005. Effectiveness of a 10-day melarsoprol schedule for the treatment of late-stage human African trypanosomiasis: confirmation from a multinational study (impamel II). J Infect Dis 191: 19221931.[Crossref]
  32. Checchi F, Piola P, Ayikoru H, Thomas F, Legros D, Priotto G, , 2007. Nifurtimox plus eflornithine for late-stage sleeping sickness in Uganda: a case series. PLoS Negl Trop Dis 1: e64.[Crossref]
  33. Berman JD, Badaro R, Thakur CP, Wasunna KM, Behbehani K, Davidson R, Kuzoe F, Pang L, Weerasuriya K, Bryceson AD, , 1998. Efficacy and safety of liposomal amphotericin B (AmBisome) for visceral leishmaniasis in endemic developing countries. Bull World Health Organ 76: 2532.
  34. Adler-Moore J, Proffitt RT, , 2002. Ambisome: liposomal formulation, structure, mechanism of action and pre-clinical experience. J Antimicrob Chemother 49 (Suppl 1): 2130.[Crossref]
http://instance.metastore.ingenta.com/content/journals/10.4269/ajtmh.2010.10-0156
Loading
/content/journals/10.4269/ajtmh.2010.10-0156
Loading

Data & Media loading...

  • Received : 12 Mar 2010
  • Accepted : 06 May 2010

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error